TP53 and breast cancer: The cytotoxic activity of these pterocarpans was evaluated against panel of nine sensitive and resistance cell lines, drug-sensitive (CCRF-CEM) and multidrug-resistant P-glycoprotein (P-gp) over expressing (CEM/ADR5000) leukemia, the (MDA-MB-231-pcDNA3) breast cancer and its resistant subline (MDA-MB-231-BCRP clone 23)(breast cancer resistance protein clone 23), the (HCT116) (p53+/+) colon cancer cells and its knockout clones (HCT116) (p53−/−), the (U87MG) glioblastoma cells and its resistant subline epidermal growth factor receptor (U87MG.